Top

Published in:

01-04-2022 | Cystic Fibrosis | Original Article

Increased Plasma YKL-40 Level and Chitotriosidase Activity in Cystic Fibrosis Patients

Authors: Dilara Bal Topcu, Gokcen Tugcu, Berrin Er, Sanem Eryilmaz Polat, Mina Hizal, Ebru Elmas Yalcin, Deniz Dogru Ersoz, Lutfi Coplu, Ugur Ozcelik, Nural Kiper, Incilay Lay, Yesim Oztas

Published in: Inflammation | Issue 2/2022

Abstract

We investigated plasma YKL-40 levels and chitotriosidase (CHIT1) activity in patients with cystic fibrosis (CF) lung disease and evaluated clinically relevant factors that may affect their levels. Plasma samples were obtained from pediatric (n = 19) and adult patients (n = 15) during exacerbation, discharge, and stable period of the disease. YKL-40 levels and chitotriosidase activity were measured by enzyme-linked immunosorbent assay and fluorometric assay, respectively. Data were compared with healthy children and adults of similar age. YKL-40 levels of pediatric and adult CF patients at all periods were significantly higher than controls (p < 0.001 and p < 0.05). CHIT1 activities of adult patients at all periods were significantly higher compared to controls (p < 0.05). On the other hand, CHIT1 activities of pediatric CF patients were similar with controls. YKL-40 levels of exacerbation period of adult CF patients were negatively correlated with forced vital capacity (FVC) (r = − 0.800, p = 0.014) and forced expiratory volume in 1 s (FEV1) (r = − 0.735, p = 0.008). YKL-40 levels in the exacerbation period of pediatric CF patients were negatively correlated with FVC (r = − 0.697, p = 0.0082) and FEV1 (r = − 0.720, p = 0.006). CHIT1 activity may be a valuable marker of chronic inflammation in adult CF patients who suffer from CF for a longer period compared to pediatric patients. Increased YKL-40 levels in both pediatric and adult patients compared to controls may point to a role in between CF pathology.

Hoffman L. R., Ramsey B. W. 2013. Cystic fibrosis therapeutics: The road ahead. Chest. 143(1):207–213.https://doi.org/10.1378/chest.12-1639

O’Sullivan B. P., Freedman S. D. 2009. Cystic fibrosis. Lancet (London, England). 373(9678):1891–1904.https://doi.org/10.1016/s0140-6736(09)60327-5

Giron-Moreno R. M., Justicia J. L., Yamamoto S., Valenzuela C., Cisneros C., Gomez-Punter R. M., Fernandes-Vasconcelos G., Ancochea J. 2014. Role of c-reactive protein as a biomarker for prediction of the severity of pulmonary exacerbations in patients with cystic fibrosis. BMC pulmonary medicine. 14:150.https://doi.org/10.1186/1471-2466-14-150

Hector, A., M.S. Kormann, I. Mack, P. Latzin, C. Casaulta, E. Kieninger, Z. Zhou, A.O. Yildirim, A. Bohla, N. Rieber, et al. 2011. The chitinase-like protein ykl-40 modulates cystic fibrosis lung disease. PLoS ONE 6 (9): e24399. https://doi.org/10.1371/journal.pone.0024399.CrossRefPubMedPubMedCentral

Lee, C.G., C.A. Da Silva, Cruz C. Dela, and S., Ahangari F., Ma B., Kang M. J., He C. H., Takyar S., Elias J. A. . 2011. Role of chitin and chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annual review of physiology. 73: 479–501. https://doi.org/10.1146/annurev-physiol-012110-142250.CrossRefPubMed

Leonardi S., Parisi G. F., Capizzi A., Manti S., Cuppari C., Scuderi M. G., Rotolo N., Lanzafame A., Musumeci M., Salpietro C. 2016. Ykl-40 as marker of severe lung disease in cystic fibrosis patients. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 15(5):583–586.https://doi.org/10.1016/j.jcf.2015.12.020

Volck, B., P.A. Price, J.S. Johansen, O. Sorensen, T.L. Benfield, H.J. Nielsen, J. Calafat, and N. Borregaard. 1998. Ykl-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proceedings of the Association of American Physicians. 110 (4): 351–360.PubMed

Fantino, E., C.L. Gangell, D. Hartl, P.D. Sly, and C.F. Arest. 2014. Airway, but not serum or urinary, levels of ykl-40 reflect inflammation in early cystic fibrosis lung disease. BMC pulmonary medicine. 14: 28. https://doi.org/10.1186/1471-2466-14-28.CrossRefPubMedPubMedCentral

Andreas, Hector, Michael S. Kormann, D., Mack Ines, Latzin Philipp, Casaulta Carmen, Kieninger Elisabeth, Zhou Zhe, Yildirim Ali Ö, Bohla Alexander, Rieber Nikolaus, et al. 2011. The chitinase-like protein ykl-40 modulates cystic fibrosis lung disease. PLoS ONE 6 (9): e24399. https://doi.org/10.1371/journal.pone.0024399.CrossRef

10.

Timo, Rath, Zwaschka Lisa, Hage Lisa, Kügler. Marion, Menendez Katrin, Naehrlich Lutz, Schulz Richard, Roderfeld Martin, and Roeb Elke. 2015. Identification of neutrophil activation markers as novel surrogate markers of cf lung disease. PLoS ONE 9 (12): e115847. https://doi.org/10.1371/journal.pone.0115847.CrossRef

11.

Ines, Mack, Hector Andreas, Ballbach Marlene, Kohlhäufl Julius, Katharina J. Fuchs, Weber Alexander, Marcus A. Mall, and Hartl Dominik. 2015. The role of chitin, chitinases, and chitinase-like proteins in pediatric lung diseases. Molecular and Cellular Pediatrics. 2: 3. https://doi.org/10.1186/s40348-015-0014-6.CrossRef

12.

Jung, Cho Soo, Michael D. Weiden, and Lee Chun Geun. 2015. Chitotriosidase in the pathogenesis of inflammation, interstitial lung diseases and copd. Allergy, Asthma & Immunology Research. 7 (1): 14–21. https://doi.org/10.4168/aair.2015.7.1.14.CrossRef

13.

Guo, Y., W. He, A.M. Boer, R.A. Wevers, A.M. de Bruijn, J.E. Groener, C.E. Hollak, J.M. Aerts, H. Galjaard, and O.P. van Diggelen. 1995. Elevated plasma chitotriosidase activity in various lysosomal storage disorders. Journal of inherited metabolic disease. 18 (6): 717–722.CrossRef

14.

Malaguarnera, L. 2006. Chitotriosidase: The yin and yang. Cellular and molecular life sciences : CMLS. 63 (24): 3018–3029. https://doi.org/10.1007/s00018-006-6269-2.CrossRefPubMed

15.

Shou-Ping Guan, Yu-Keung Mok, Khai-Nee Koo, Kai-Ling Chu, Wong W. S. Fred. 2009. Chitinases: Biomarkers for human diseases. Protein & Peptide Letters. 16(5):490–498. https://doi.org/10.2174/092986609788167842

16.

Tiddens, H., M. Silverman, and A. Bush. 2000. The role of inflammation in airway disease: Remodeling. American journal of respiratory and critical care medicine. 162 (2 Pt 2): S7-s10. https://doi.org/10.1164/ajrccm.162.supplement_1.maic-2.CrossRefPubMed

17.

Hector A., Chotirmall S. H., Lavelle G. M., Mirkovic B., Horan D., Eichler L., Mezger M., Singh A., Ralhan A., Berenbrinker S. et al. 2016. Chitinase activation in patients with fungus-associated cystic fibrosis lung disease. J Allergy Clin Immunol. 138(4):1183–1189 e1184.https://doi.org/10.1016/j.jaci.2016.01.031

18.

De Boeck, K., N. Derichs, I. Fajac, H.R. de Jonge, I. Bronsveld, I. Sermet, F. Vermeulen, D.N. Sheppard, H. Cuppens, M. Hug, et al. 2011. New clinical diagnostic procedures for cystic fibrosis in Europe. Journal of cystic fibrosis : Official journal of the European Cystic Fibrosis Society. 10 (Suppl 2): S53-66. https://doi.org/10.1016/s1569-1993(11)60009-x.CrossRef

19.

Lucas Jane S, Burgess Andrea, Mitchison Hannah M, Moya Eduardo, Williamson Michael, Hogg Claire. 2014. Diagnosis and management of primary ciliary dyskinesia. Archives of Disease in Childhood. 99(9):850–856.https://doi.org/10.1136/archdischild-2013-304831

20.

Goss C. H., Burns J. L. 2007. Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax. 62(4):360–367. https://doi.org/10.1136/thx.2006.060889

21.

Dakin, C., R.L. Henry, P. Field, and J. Morton. 2001. Defining an exacerbation of pulmonary disease in cystic fibrosis. Pediatric pulmonology. 31 (6): 436–442. https://doi.org/10.1002/ppul.1072.CrossRefPubMed

22.

Hafen, G.M., S.C. Ranganathan, C.F. Robertson, and P.J. Robinson. 2006. Clinical scoring systems in cystic fibrosis. Pediatric pulmonology. 41 (7): 602–617. https://doi.org/10.1002/ppul.20376.CrossRefPubMed

23.

Ambrosino Nicolino, G., and Scano. . 2004. Dyspnoea and its measurement. Breathe. 1: 101–107. https://doi.org/10.1183/18106838.0102.100.CrossRef

24.

Bilton D., Canny G., Conway S., Dumcius S., Hjelte L., Proesmans M., Tümmler B., Vavrova V., De Boeck K. 2011. Pulmonary exacerbation: Towards a definition for use in clinical trials. Report from the EuroCareCF working group on outcome parameters in clinical trials. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. 10 Suppl 2:S79–81. https://doi.org/10.1016/s1569-1993(11)60012-x

25.

Miller, M.R., J. Hankinson, V. Brusasco, F. Burgos, R. Casaburi, A. Coates, R. Crapo, P. Enright, C.P. van der Grinten, P. Gustafsson, et al. 2005. Standardisation of spirometry. European Respiratory Journal 26 (2): 319–338. https://doi.org/10.1183/09031936.05.00034805.CrossRef

26.

Quanjer, P.H., S. Stanojevic, T.J. Cole, X. Baur, G.L. Hall, B.H. Culver, P.L. Enright, J.L. Hankinson, M.S. Ip, J. Zheng, et al. 2012. Multi-ethnic reference values for spirometry for the 3–95-yr age range: The global lung function 2012 equations. European Respiratory Journal 40 (6): 1324–1343. https://doi.org/10.1183/09031936.00080312.CrossRef

27.

Graham B. L., Steenbruggen I., Miller M. R., Barjaktarevic I. Z., Cooper B. G., Hall G. L., Hallstrand T. S., Kaminsky D. A., McCarthy K., McCormack M. C. et al. 2019. Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement. American journal of respiratory and critical care medicine. 200(8):e70-e88. https://doi.org/10.1164/rccm.201908-1590ST

28.

Hollak C. E., van Weely S., van Oers M. H., Aerts J. M. 1994. Marked elevation of plasma chitotriosidase activity. A novel hallmark of gaucher disease. The Journal of clinical investigation. 93(3):1288–1292. https://doi.org/10.1172/jci117084

29.

Boot R. G., Renkema G. H., Verhoek M., Strijland A., Bliek J., de Meulemeester T. M., Mannens M. M., Aerts J. M. 1998. The human chitotriosidase gene. Nature of inherited enzyme deficiency. The Journal of biological chemistry. 273(40):25680–25685. https://doi.org/10.1074/jbc.273.40.25680

30.

Döring G., Conway Steven, Heijerman Harry, Hodson Margaret, Høiby Niels, Smyth Alan, Touw Daan. 2000. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: A European consensus. The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology. 16:749–767.https://doi.org/10.1034/j.1399-3003.2000.16d30.x

31.

Lee, Tim W., and R., Brownlee Keith G., Conway Steven P., Denton Miles, Littlewood James M. . 2003. Evaluation of a new definition for chronic — Pseudomonas aeruginosa — infection in cystic fibrosis patients. Journal of Cystic Fibrosis. 2 (1): 29–34. https://doi.org/10.1016/S1569-1993(02)00141-8.CrossRefPubMed

32.

Harlander, M., D. Lestan, and M. Turel. 2020. Chitotriosidase activity in plasma and copd exacerbations. Lung 198 (2): 299–306. https://doi.org/10.1007/s00408-020-00331-8.CrossRefPubMed

33.

Rohit, Ramanathan, Kohli Anita, Ingaramo María Clara, Jain Alka, Sean X. Leng, Naresh M. Punjabi, Jeremy D. Walston, and Neal S. Fedarko. 2013. Serum chitotriosidase, a putative marker of chronically activated macrophages, increases with normal aging. Journals of Gerontology. Series A, Biological Sciences and Medical Sciences 68 (10): 1303–1309. https://doi.org/10.1093/gerona/glt022.CrossRef

34.

Sebastian, Majewski, Tworek Damian, Szewczyk Karolina, Kiszałkiewicz Justyna, Kurmanowska Zofia, Brzeziańska-Lasota. Ewa, Jerczyńska Hanna, Antczak Adam, Piotrowski Wojciech Jerzy, and Górski. Paweł. 2019. Overexpression of chitotriosidase and ykl-40 in peripheral blood and sputum of healthy smokers and patients with chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 14: 1611–1631. https://doi.org/10.2147/COPD.S184097.CrossRef

35.

James, Anna J., Lovisa E. Reinius, Verhoek Marri, Gomes Anna, Kupczyk Maciej, Hammar Ulf, Ono Junya, Ohta Shoichiro, Izuhara Kenji, Bel Elisabeth, et al. 2016. Increased ykl-40 and chitotriosidase in asthma and chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine. 193 (2): 131–142. https://doi.org/10.1164/rccm.201504-0760oc.CrossRefPubMed

36.

David, Bennett, Cameli Paolo, Lanzarone Nicola, Carobene Loredana, Bianchi Nicola, Fui Annalisa, Rizzi Luigi, Bergantini Laura, Cillis Giuseppe, d’Alessandro Miriana, et al. 2020. Chitotriosidase: A biomarker of activity and severity in patients with sarcoidosis. Respiratory research. 21 (1): 6–6. https://doi.org/10.1186/s12931-019-1263-z.CrossRef

37.

Hector, A., S.H. Chotirmall, G.M. Lavelle, B. Mirković, D. Horan, L. Eichler, M. Mezger, A. Singh, A. Ralhan, S. Berenbrinker, et al. 2016. Chitinase activation in patients with fungus-associated cystic fibrosis lung disease. The Journal of Allergy and Clinical Immunology 138 (4): 1183-1189.e1184. https://doi.org/10.1016/j.jaci.2016.01.031.CrossRefPubMed

38.

Coriati Adèle Massé Chantal Ménard Aurélie Bouvet Guillaume Berthiaume Yves 2018 Neutrophils as a potential source of chitinase-3-like protein 1 in cystic fibrosis Inflammation 41 https://doi.org/10.1007/s10753-018-0806-7

39.

Lai, T., D. Wu, M. Chen, C. Cao, Z. Jing, L. Huang, Y. Lv, X. Zhao, Q. Lv, Y. Wang, et al. 2016. Ykl-40 expression in chronic obstructive pulmonary disease: Relation to acute exacerbations and airway remodeling. Respiratory Research 17: 31. https://doi.org/10.1186/s12931-016-0338-3.CrossRefPubMedPubMedCentral

40.

Majewski, S., D. Tworek, K. Szewczyk, J. Kiszalkiewicz, Z. Kurmanowska, E. Brzezianska-Lasota, H. Jerczynska, A. Antczak, W.J. Piotrowski, and P. Gorski. 2019. Overexpression of chitotriosidase and ykl-40 in peripheral blood and sputum of healthy smokers and patients with chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 14: 1611–1631. https://doi.org/10.2147/COPD.S184097.CrossRefPubMedPubMedCentral

41.

Konradsen J. R., James A., Nordlund B., Reinius L. E., Soderhall C., Melen E., Wheelock A. M., Lodrup Carlsen K. C., Lidegran M., Verhoek M. et al. 2013. The chitinase-like protein ykl-40: A possible biomarker of inflammation and airway remodeling in severe pediatric asthma. J Allergy Clin Immunol. 132(2):328–335 e325. https://doi.org/10.1016/j.jaci.2013.03.003

42.

Santos, C.B., J. Davidson, R.A. Covar, and J.D. Spahn. 2014. The chitinase-like protein ykl-40 is not a useful biomarker for severe persistent asthma in children. Annals of Allergy, Asthma & Immunology 113 (3): 263–266. https://doi.org/10.1016/j.anai.2014.05.024.CrossRef

43.

Leonardi, S., M. Filippelli, A. Lanzafame, G. Parisi, G. Mistrello, M. Musumeci, V. Torrisi, S. Musumeci, and C. Cuppari. 2015. Serum ykl-40 in children with asthma. Journal of Biological Regulators and Homeostatic Agents 29 (2 Suppl 1): 114–119.PubMed

44.

Gomez, Jose L., Xiting Yan, Carole T. Holm, Nicole Grant, Qing Liu, Lauren Cohn, Vera Nezgovorova V., Meyers D. A., Bleecker E. R., Crisafi G. M. et al. 2017. Characterisation of asthma subgroups associated with circulating ykl-40 levels. Europe Respiratory Journal 50(4). https://doi.org/10.1183/13993003.00800-2017

45.

Liu, L., X. Zhang, Y. Liu, L. Zhang, J. Zheng, J. Wang, P.M. Hansbro, L. Wang, G. Wang, and A.C. Hsu. 2019. Chitinase-like protein ykl-40 correlates with inflammatory phenotypes, anti-asthma responsiveness and future exacerbations. Respiratory Research 20 (1): 95. https://doi.org/10.1186/s12931-019-1051-9.CrossRefPubMedPubMedCentral

46.

Coriati, A., G.F. Bouvet, C. Massé, T. Ducruet, and Y. Berthiaume. 2020. Ykl-40 as a clinical biomarker in adult patients with cf: Implications of a chi3l1 single nucleotide polymorphism in disease severity. Journal of cystic fibrosis : Official journal of the European Cystic Fibrosis Society. https://doi.org/10.1016/j.jcf.2020.11.011.CrossRef

Title: Increased Plasma YKL-40 Level and Chitotriosidase Activity in Cystic Fibrosis Patients
Authors: Dilara Bal Topcu
Gokcen Tugcu
Berrin Er
Sanem Eryilmaz Polat
Mina Hizal
Ebru Elmas Yalcin
Deniz Dogru Ersoz
Lutfi Coplu
Ugur Ozcelik
Nural Kiper
Incilay Lay
Yesim Oztas
Publication date: 01-04-2022
Publisher: Springer US
Keywords: Cystic Fibrosis
Cystic Fibrosis
Published in: Inflammation / Issue 2/2022
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-021-01572-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Increased Plasma YKL-40 Level and Chitotriosidase Activity in Cystic Fibrosis Patients

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2022

Mast Cells Modulate the Immune Response and Redox Status of the Gastrointestinal Tract in Induced Venom Pathogenesis

LASSBio-596: a New Pre-clinical Candidate for Rheumatoid Arthritis?

Performance of High Mobility Protein Group 1 and Interleukin-6 as Predictors of Outcomes Resulting from Variceal Bleeding in Patients with Advanced Chronic Liver Disease

Association of miR-155, miR-187 and Inflammatory Cytokines IL-6, IL-10 and TNF-α in Chronic Opium Abusers

TLR4-IN-C34 Inhibits Lipopolysaccharide-Stimulated Inflammatory Responses via Downregulating TLR4/MyD88/NF-κB/NLRP3 Signaling Pathway and Reducing ROS Generation in BV2 Cells

Neutrophil Extracellular Trap Formation Potential Correlates with Lung Disease Severity in COVID-19 Patients

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page